Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 6,983 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Carcinoma of the Breast Clear all
Completed Not applicable Interventional

Young, Empowered & Strong (YES): The Young Women's Breast Cancer Study 2- Focus on Intervention Pilot

NCT03913936
View directory record Official record
Conditions
Breast Cancer
Interventions
YES portal
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 17, 2026, 2:29 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)

NCT04436744
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Giredestrant, Anastrozole, Palbociclib, Surgery
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Burbank, California • Laguna Hills, California • San Luis Obispo, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 17, 2026, 2:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Exemestane 25 mg Tablet Under Fed Conditions

NCT01331434
View directory record Official record
Conditions
Breast Cancer
Interventions
exemestane
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 17, 2026, 2:29 PM EDT
Completed No phase listed Observational

Evaluating Patient Reported Outcomes in Radiation Therapy, the PRO-RT Study

NCT05224271
View directory record Official record
Conditions
Breast Carcinoma, Head and Neck Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm
Interventions
Electronic Health Record Review, Medical Device Usage and Evaluation, Survey Administration
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 17, 2026, 2:29 PM EDT
Completed Phase 1Phase 2 Interventional

Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin

NCT00773344
View directory record Official record
Conditions
Solid Tumors, Breast Cancer
Interventions
Tanespimycin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Scottsdale, Arizona • Tucson, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 17, 2026, 2:29 PM EDT
Terminated Phase 2 Interventional Results available

Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer

NCT00096109
View directory record Official record
Conditions
Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
tanespimycin, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 17, 2026, 2:29 PM EDT
Recruiting Not applicable Interventional

A Randomized Two-Arm Proof of Concept Study Testing A Novel Approach to Exercise Promotion Based on Affect-regulation

NCT06258993
View directory record Official record
Conditions
Breast Cancer
Interventions
Core Exercise Promotion Program, Affect-based exercise prescription, Effort-based exercise prescription
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 17, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery

NCT00348699
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Recurrent Renal Cell Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer, Stage IV Renal Cell Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
AFP464, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 24, 2014 · Synced Oct 17, 2026, 2:29 PM EDT
Not listed Phase 1 Interventional

Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer

NCT03775525
View directory record Official record
Conditions
Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach, Lymphoma, Sarcoma, Cutaneous T Cell Lymphoma, Head and Neck Squamous Cell Carcinoma, Basal Cell Carcinoma, Cutaneous T-cell Lymphoma, Cutaneous Squamous Cell Carcinoma
Interventions
GZ17-6.02, Capecitabine
Drug
Lead sponsor
Genzada Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Scottsdale, Arizona • Los Angeles, California • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 17, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer

NCT02632071
View directory record Official record
Conditions
Metastatic Breast Cancer, Breast Carcinoma
Interventions
ACY-1215, Nab-paclitaxel
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 17, 2026, 2:29 PM EDT
Completed No phase listed Observational

Promoting Breast Cancer Screening in Non-adherent Women

NCT01332032
View directory record Official record
Conditions
Breast Cancer
Interventions
Reminder Letter, Reminder Call, Counselor Call
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
40 Years to 84 Years · Female only
Enrollment
36,348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 17, 2026, 2:29 PM EDT
Completed Not applicable Interventional

Mindfulness-Based Stress Reduction in Helping Participants With Metastatic Breast Cancer

NCT03683147
View directory record Official record
Conditions
Stage IV Breast Cancer
Interventions
Laboratory Biomarker Analysis, Meditation-Based Stress Reduction Program, Quality-of-Life Assessment, Questionnaire Administration
Other · Behavioral
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2024 · Synced Oct 17, 2026, 2:29 PM EDT
Terminated Not applicable Interventional

PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer

NCT01712815
View directory record Official record
Conditions
HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
laboratory biomarker analysis, pharmacological study, questionnaire administration, fluorine F 18-clevudine, positron emission tomography/computed tomography
Other · Radiation · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 17, 2026, 2:29 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer

NCT00365599
View directory record Official record
Conditions
Breast Cancer
Interventions
suberoylanilide hydroxamic acid (SAHA, Vorinostat), tamoxifen citrate (Tamoxifen)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
8
States / cities
San Francisco, California • Boynton Beach, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 17, 2026, 2:29 PM EDT
Recruiting Not applicable Interventional

Breast Re-irradiation After Second Ipsilateral Lumpectomy

NCT06867484
View directory record Official record
Conditions
Breast Cancer, Cancer, Cancer of the Breast, HER2-negative Breast Cancer, ER+ Breast Cancer, Estrogen-receptor-positive Breast Cancer
Interventions
Intensity modulated radiation therapy (IMRT)
Radiation
Lead sponsor
Youssef Zeidan
Other
Eligibility
40 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
2
States / cities
Boca Raton, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 17, 2026, 2:29 PM EDT
Completed Phase 2 Interventional

A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients

NCT00001384
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Adriamycin, cyclophosphamide, G-CSF, paclitaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 2:29 PM EDT
Withdrawn Phase 1 Interventional

Vaccine Response With NT-I7

NCT04054752
View directory record Official record
Conditions
Breast Carcinoma, Colorectal Adenocarcinoma, Bladder Carcinoma
Interventions
Recombinant human IL-7-hyFc (NT-I7), Vaccine sequence 1, Vaccine sequence 2
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
60 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 17, 2026, 2:29 PM EDT
Completed Phase 2 Interventional

Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer

NCT00080743
View directory record Official record
Conditions
Breast Cancer
Interventions
gefitinib, tamoxifen citrate, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 6, 2009 · Synced Oct 17, 2026, 2:29 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

1380GCC: Prospective Study of GP-88 Blood Test in Healthy Women With Baseline Gail Model Risk Assessment Undergoing Screening for Breast Cancer

NCT02700776
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Phlebotomy - Blood sampling for GP88 at MM, SOC Tissue biopsy
Other · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
40 Years to 64 Years · Female only
Enrollment
417 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Glen Burnie, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 17, 2026, 2:29 PM EDT
Withdrawn Phase 4 Interventional

Pectoral Nerve Blockade in Mastectomy

NCT01943240
View directory record Official record
Conditions
Postoperative Pain, Breast Cancer
Interventions
Paravertebral nerve block: 4 mL ropivacaine 0.5% at each of six levels, 10 cc of 0.375% ropivacaine pectoral nerve block
Drug
Lead sponsor
Timothy R Petersen
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 17, 2026, 2:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cancer Survivor Registry: The Breast Cancer M.A.P. (Mind Affects the Physical) Project

NCT01295658
View directory record Official record
Conditions
Cancers
Interventions
Not listed
Lead sponsor
Cancer Support Community, Research and Training Institute, Philadelphia
Other
Eligibility
18 Years and older
Enrollment
3,729 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 17, 2026, 2:29 PM EDT
Completed Not applicable Interventional

A mHealth Behavioral Cancer Pain Protocol for Medically Underserved Communities

NCT02783755
View directory record Official record
Conditions
Breast Cancer
Interventions
Device: smartphone
Behavioral
Lead sponsor
Duke University
Other
Eligibility
21 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 17, 2026, 2:29 PM EDT
Terminated Phase 4 Interventional Results available

Performance of Contrast-Enhanced Spectral Mammography to Assess Neoadjuvant Chemotherapy Response (CEDM)

NCT04625517
View directory record Official record
Conditions
Breast Cancer
Interventions
Digital Mammography, Low Osmolar Contrast Material, 300-399 Mg/Ml Iodine Concentration, Per Ml
Procedure · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 17, 2026, 2:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Combined Breast Cancer Risk Study

NCT03067389
View directory record Official record
Conditions
Hereditary Cancer
Interventions
Diagnostic test
Diagnostic Test
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years to 84 Years · Female only
Enrollment
553 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
4
States / cities
Fayetteville, Arkansas • Boynton Beach, Florida • Hyannis, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 17, 2026, 2:29 PM EDT